Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia
- PMID: 38735758
- DOI: 10.1111/bjh.19524
Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia
References
REFERENCES
-
- Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
-
- Laetsch TW, Maude SL, Rives S, Hiramatsu H,Bittencourt H,Bader P, et al. Three‐year update of Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664–1169.
-
- Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, et al. Updated analysis of the efficacy and safety of Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):895.
-
- Schultz LM, Baggott C, Prabhu S, Pacenta H, Phillips CL, Rossoff J, et al. Disease burden impacts outcomes in pediatric and young adult B‐cell acute lymphoblastic leukemia after commercial Tisagenlecleucel: results from the pediatric real world CAR consortium (PRWCC). Blood. 2020;136(Supplement 1):14–15.
-
- Dourthe M‐E, Rabian F, Yakouben K, Chevillon F, Cabannes‐Hamy A, Méchinaud F, et al. Determinants of CD19‐positive vs CD19‐negative relapse after tisagenlecleucel for B‐cell acute lymphoblastic leukemia. Leukemia. 2021;35(12):3383–3393.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources